Entera Bio Ltd. announced that it has been selected to present data for its investigational agent EB613 at the ASBMR 2023 Annual Meeting on October 13-16, 2023 in Vancouver, BC, Canada. EB613 [hPTH(1-34) tablets] is being developed as the first once-daily oral anabolic (bone forming) mini tablet therapy for post-menopausal women with high risk osteoporosis. It is estimated that 54 million adults, representing 50% of the U.S. adult population over age 50, are at risk of a fragility fracture and approximately 1 in 5 older adults will die within the year following a hip fracture.

Due to a lower peak bone density as compared to men and decreases in estradiol after menopause, women are affected in greater numbers. Post menopausal osteoporosis afflicts more women globally than cancer and cardiovascular disease and is a serious health concern. Abstract Title: Pharmacokinetic (PK) Profile of EBP05/EB613 Oral Teriparatide Tablets in Women of Post Menopausal Age Versus Young Adult Men Presentation Number: SAT-456 Presentation Type: Poster Presentation Session: Poster Session I Session Date/Time: Saturday, October 14, 2023, 1:30 pm ?

3:00 pm. Abstract Title: First Oral hPTH(1-34) Tablet Treatment for Osteoporosis Demonstrates Rapid Pharmacodynamic Effect on Plasma Levels of Endogenous PTH(1-84) Presentation Number: LB SUN-646 Presentation Type: Late Breaking Poster Presentation Session: Late-Breaking Poster Session I Session Date/Time: Sunday, October 15, 2023, 1:30 pm ? 3:00 pm Presentation Time: 1:30 pm ?

3:00 pm.